EP4698206A1 - Decorinbasierte zusammensetzungen zur reparatur und regeneration von retinalem pigmentepithel - Google Patents

Decorinbasierte zusammensetzungen zur reparatur und regeneration von retinalem pigmentepithel

Info

Publication number
EP4698206A1
EP4698206A1 EP24719197.6A EP24719197A EP4698206A1 EP 4698206 A1 EP4698206 A1 EP 4698206A1 EP 24719197 A EP24719197 A EP 24719197A EP 4698206 A1 EP4698206 A1 EP 4698206A1
Authority
EP
European Patent Office
Prior art keywords
sequence
protein
nucleic acid
acid sequence
fragment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP24719197.6A
Other languages
English (en)
French (fr)
Inventor
Thierry Bordet
Karine Bigot
Laura BENICHOU
Francine Behar-Cohen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pulsesight Therapeutics
Assistance Publique Hopitaux de Paris APHP
Institut National de la Sante et de la Recherche Medicale INSERM
Sorbonne Universite
Universite Paris Cite
Original Assignee
Pulsesight Therapeutics
Assistance Publique Hopitaux de Paris APHP
Institut National de la Sante et de la Recherche Medicale INSERM
Sorbonne Universite
Universite Paris Cite
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pulsesight Therapeutics, Assistance Publique Hopitaux de Paris APHP, Institut National de la Sante et de la Recherche Medicale INSERM, Sorbonne Universite, Universite Paris Cite filed Critical Pulsesight Therapeutics
Publication of EP4698206A1 publication Critical patent/EP4698206A1/de
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/179—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A61K48/0058—Nucleic acids adapted for tissue specific expression, e.g. having tissue specific promoters as part of a contruct
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0075—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the delivery route, e.g. oral, subcutaneous
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
EP24719197.6A 2023-04-21 2024-04-19 Decorinbasierte zusammensetzungen zur reparatur und regeneration von retinalem pigmentepithel Pending EP4698206A1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR2304056 2023-04-21
PCT/EP2024/060741 WO2024218311A1 (fr) 2023-04-21 2024-04-19 Compositions à base de décorine pour la réparation et la régéneration de l'épithélium pigmentaire de la rétine

Publications (1)

Publication Number Publication Date
EP4698206A1 true EP4698206A1 (de) 2026-02-25

Family

ID=87974310

Family Applications (1)

Application Number Title Priority Date Filing Date
EP24719197.6A Pending EP4698206A1 (de) 2023-04-21 2024-04-19 Decorinbasierte zusammensetzungen zur reparatur und regeneration von retinalem pigmentepithel

Country Status (2)

Country Link
EP (1) EP4698206A1 (de)
WO (1) WO2024218311A1 (de)

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH07508403A (ja) 1992-04-03 1995-09-21 ラ　ホヤ　キャンサー　リサーチ　ファウンデーション デコリンフラグメントおよび細胞調節因子を阻害する方法
EP1758931A1 (de) 2004-05-31 2007-03-07 National University of Singapore Von leucinreichen wiederholungseinheiten von decorin gewonnene peptide und anwendungen davon
CA2967156C (en) 2005-04-18 2021-06-01 Francine Behar-Cohen Improved methods and devices for delivering a therapeutic product to the ocular sphere of a subject.
WO2007120457A2 (en) 2006-04-13 2007-10-25 Euclid Systems Corporation Composition and method for stabilizing corneal tissue after refractive surgery
DK3108933T3 (da) 2008-01-07 2019-11-25 Salutaris Medical Devices Inc Indretninger til minimal-invasiv extraokulær levering af radiation til posterior del af øjet
JP2013512924A (ja) 2009-12-04 2013-04-18 ユークリッド システムズ コーポレイション 黄斑変性、糖尿病性網膜症および糖尿病黄斑浮腫の予防および治療のための組成物および方法
HUE044778T2 (hu) * 2011-11-14 2019-11-28 Astellas Inst For Regenerative Medicine Humán RPE sejt gyógyászati készítmények és alkalmazásaik
US8663150B2 (en) 2011-12-19 2014-03-04 Ivantis, Inc. Delivering ocular implants into the eye
KR102863726B1 (ko) 2014-05-02 2025-09-25 젠자임 코포레이션 망막 및 cns 유전자 요법을 위한 aav 벡터
WO2019229116A1 (en) 2018-05-31 2019-12-05 INSERM (Institut National de la Santé et de la Recherche Médicale) Intravitreal delivery of a decorin polypeptide for the treatment of choroidal neovascularisation
FR3111913A1 (fr) * 2020-06-30 2021-12-31 Eyevensys Construction d’adn pour le traitement de pathologies oculaires

Also Published As

Publication number Publication date
WO2024218311A1 (fr) 2024-10-24

Similar Documents

Publication Publication Date Title
Tawfik et al. Nanomedicine and drug delivery to the retina: current status and implications for gene therapy
Li et al. Nanoparticulate drug delivery to the retina
US20090011040A1 (en) Use of compacted nucleic acid nanoparticles in non-viral treatments of ocular diseases
Lavik et al. Novel drug delivery systems for glaucoma
JP6220785B2 (ja) 被験者における眼疾患の処置のための方法および薬学的組成物
US20220008546A1 (en) Polypeptide-based ocular absorption enhancer and application thereof
CN113348249A (zh) 内蛋白及其用途
CN109072241A (zh) 具有改善的玻璃体内半衰期的组合物及其用途
WO2009047766A2 (en) Composition and method for the treatment or prevention of glaucoma and ocular hypertension
Selvaraj et al. Current treatment strategies and nanocarrier based approaches for the treatment and management of diabetic retinopathy
JP2024055984A (ja) 神経栄養剤、アポトーシスシグナリング断片阻害剤（ＦＡＳ）もしくはＦＡＳリガンド（ＦＡＳＬ）阻害剤、腫瘍壊死因子α（ＴＮＦ－α）もしくはＴＮＦ受容体阻害剤、ミトコンドリアペプチド、オリゴヌクレオチド、ケモカイン阻害剤、またはシステイン－アスパラギン酸プロテアーゼを含む薬物送達システム
Zarbin et al. Regenerative nanomedicine for vision restoration
Mehta et al. Approaches in topical ocular drug delivery and developments in the use of contact lenses as drug-delivery devices
WO2023091955A1 (en) Compositions and methods for the treatment of ocular diseases and injuries
Hurst et al. The future of nanomaterials tackling the challenge of delivering nucleic acids to the retina
Wang et al. Recent advances and prospects of nanoparticle-based drug delivery for diabetic ocular complications
CA3122229A1 (en) Composition for and method of facilitating corneal tissue repair
JP2010511692A (ja) イオントフォレシスを通じての核酸の強化された網膜送達
US7943590B2 (en) Compositions and methods for treating ophthalmic disorders
Ellis‐Behnke et al. Redefining tissue engineering for nanomedicine in ophthalmology
Ge et al. Exosomes in treating eye diseases: targeting strategies
WO2024218311A1 (fr) Compositions à base de décorine pour la réparation et la régéneration de l'épithélium pigmentaire de la rétine
EP4171636A1 (de) Dna-struktur zur behandlung von augenerkrankungen
EP3893918B1 (de) Vasodilatoren zur verwendung bei der behandlung einer ischämischen erkrankung der netzhaut
Naser et al. Ocular Gene Therapy

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: UNKNOWN

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20251017

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC ME MK MT NL NO PL PT RO RS SE SI SK SM TR